[18F] AlF-NOTA-PCP2 PET/CT to Assess PD-L1 Status in Head and Neck Cancer: Head-to-Head Comparison With [: 18: F] FDG PET/CT
用户sToGMn7iJdc8
24天前
52
10
已完结
1. 系统已在2026-02-04 11:21:19对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
其他信息:
Y Wang, Z Liu, Y Li, K He, X Ding, K Teng…
Clinical Nuclear …, 2026
journals.lww.com
Purpose: While PD-L1 expression heterogeneity limits the predictive value of localized biopsies, molecular imaging offers a dynamic alternative. We developed [18 F] AlF-NOTA-PCP2, a hydrophilic PD-L1–targeted peptide tracer, and first evaluated its clinical utility in head and neck (HNC) cancer through a head-to-head comparison with [18 F] FDG PET/CT. Methods: Preclinical validation included competitive binding assays and micro-PET/CT in PD-L1–positive HNC xenografts. A prospective trial (NCT04304066) enrolled 24 HNC …
